UCB says U.S. FDA committee recommends its drug Cimzia for new uses

Wednesday, July 24, 2013

UCB says U.S. FDA committee recommends its drug Cimzia for new uses

UCB says U.S. FDA committee recommends its drug Cimzia for new uses

BRUSSELS | Wed Jul 24, 2013 1:19am EDT

(Reuters) - Belgian pharmaceutical group UCB SA said a committee of the U.S. Food and Drug Administration voted in favor of allowing UCB's arthritis drug Cimzia to be used to treat adults with active axial spondyloarthritis.

While the vote was not binding on a final recommendation, it would play a part in the decision to clear the drug for this application in the United States, UCB said.

Axial spondyloarthritis is an inflammatory disease mostly affecting the spine and the pelvis.

(Reporting by Robert-Jan Bartunek; Editing by Matt Driskill)

This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers. Five Filters recommends: 'You Say What You Like, Because They Like What You Say' - http://www.medialens.org/index.php/alerts/alert-archive/alerts-2013/731-you-say-what-you-like-because-they-like-what-you-say.html